Type 2 diabetes is a serious medical problem nowadays, particularly when considering increasing number of diabetic patients in the world. Previous therapy of this disease, beside behavioral treatment, was based on oral antidiabetic agents and insulin as monotherapy or combination. Currently incretin hormons are of significant interest. These are gut hormones which stimulate β cells to insulin secretion in a glucose-dependent manner. Exenatid – GLP-1 receptor agonist – is a representative of new group of agents which improve incretin effect. The aim of the article was to define role of this drug in the treatment of type 2 diabetic patients